Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in persons with overweight or obesity. METHODS: In a phase 3, double-blind, placebo-controlled trial in China, we randomly assigned, in a 1:1:1 ratio, adults 18 to 75 years of age who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 28 or had a BMI of 24 to less than 28 plus at least one weight-related coexisting condition to receive 4 mg of mazdutide, 6 mg of mazdutide, or placebo for 48 weeks. The two primary end points were the percentage change in body weight from baseline and a weight reduction of at least 5% at week 32, as assessed in a treatment-policy estimand analysis (which assessed effects regardless of early discontinuation of mazdutide or placebo and the initiation of new antiobesity therapies). RESULTS: Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline. At week 32, the mean percentage change in body weight from baseline was -10.09% (95% confidence interval [CI], -11.15 to -9.04) in the 4-mg mazdutide group, -12.55% (95% CI, -13.64 to -11.45) in the 6-mg mazdutide group, and 0.45% (95% CI, -0.61 to 1.52) in the placebo group, and 73.9%, 82.0%, and 10.5% of the participants, respectively, had a weight reduction of at least 5% (P<0.001 for all comparisons with placebo). At week 48, the mean percentage change in body weight from baseline was -11.00% (95% CI, -12.27 to -9.73) in the 4-mg mazdutide group, -14.01% (95% CI, -15.36 to -12.66) in the 6-mg mazdutide group, and 0.30% (95% CI, -0.98 to 1.58) in the placebo group, and 35.7%, 49.5%, and 2.0% of the participants, respectively, had a weight reduction of at least 15% (P<0.001 for all comparisons with placebo). Beneficial effects on all prespecified cardiometabolic measures were seen with mazdutide. The most frequently reported adverse events were gastrointestinal and mostly mild to moderate in severity. The incidence of adverse events leading to discontinuation of the trial regimen was 1.5% with the 4-mg mazdutide dose, 0.5% with the 6-mg mazdutide dose, and 1.0% with placebo. CONCLUSIONS: In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg or 6 mg for 32 weeks led to clinically relevant reductions in body weight. (Funded by Innovent Biologics; GLORY-1 ClinicalTrials.gov number, NCT05607680.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With mazdutide treatment, 51% of participants experienced nausea and 43% experienced vomiting, but drug discontinuation rate due to adverse events was low (2%; table).126,134”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [134]
In the citing paper
“a recent phase 3 trial (GLORY) described bodyweight reductions after 48 weeks of treatment with 6 mg/week mazdutide of 14•0% (vs an increase of 0•3% with placebo).134”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [134]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationEpidemiology and determinants of obesity in China
Pan, X.-F., Wang, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00045-0 · Cited by 1,554
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Chen, K., Shen, Z., Gu, W., Lyu, Z., Qi, X., Mu, Y., Ning, Y., & for the Meinian Investigator Group (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15238 · Cited by 393
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Clinical management and treatment of obesity in China
Zeng, Q., Li, N., Pan, X.-F., Chen, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00047-4 · Cited by 269
Self-citationLocalio, A. R., Margolis, D. J., & Berlin, J. A. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.12.001 · Cited by 259
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
“The innovation underlying dual and even triple receptor agonists lies in their single-molecule architecture, which represents a significant advancement in peptide bioengineering.”
Self-citationMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux, C. W., Wharton, S., Startseva, E., Kloer, I. M., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., Bogdański, P., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600751 · Cited by 33
Self-citationObesity in China: current progress and future prospects
Pan, X., Fang, Z.-Z., Zhang, L., & Pan, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00357-2 · Cited by 24
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15
“…other gut hormone-based obesity treatments are currently being investigated in clinical trials, such as GLP-1/ GIP/Glucagon triple receptor agonist (retatrutide), 9 GLP-1/Glucagon receptor dual agonist (survodutide and mazdutide) 10,11 and Amylin/ GLP-1 receptor agonist (CagriSema and Amycretin).”
Shirley, M. (2025) · Drugs · doi:10.1007/s40265-025-02249-y · Cited by 15
Qin, S., Luo, M., Liu, S., Sun, C., Yin, J., Peng, C., & Li, D. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157612 · Cited by 16
Mazdutide versus placebo in Chinese adults with type 2 diabetes
Zhu, D., Zhao, J., Cai, H., Chu, X., Xiu, S., Song, C., Cheng, Z., Cao, H., Jiang, H., Zhang, L., et al. (2025) · Nature · doi:10.1038/s41586-025-10026-w · Cited by 21
Self-citationMazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Bhattachar, S., Tham, L. S., Yan, L., Chua, L., Ng, S., Tang, Y., Ibriga, H., Ni, W., Gurbuz, S., Mather, K. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70040 · Cited by 15
“21 The objectives of this Phase 1 study were to determine the safety, tolerability, pharmacokinetics (PK) profile, and pharmacodynamic effects of mazdutide administered weekly up to a dose of 16 mg in adults with overweight or obesity without diabetes.”
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“In a subsequent phase III study, 48 weeks of treatment with once-weekly mazdutide 6.0 mg resulted in a placebo-corrected weight loss of 14.7%, alongside improvements in biomarkers of cardio-vascular and liver health 23 .”
InfluentialChrysavgis, L., Mourelatou, N. G., Koloutsou, M. E., Rozani, S., & Cholongitas, Ε. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412130 · Cited by 16
“Similarly, phase III data from mazdutide, a GLP-1/glucagon dual agonist, demonstrated significant total weight loss in a dose-dependent manner in Chinese population with overweight or obesity [130].”
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70196 · Cited by 9
“Of the two most clinically advanced compounds, mazdutide is an oxyntomodulin analogue, 45 whereas survodutide is derived from the 29-residue human glucagon peptide with several amino acid substitutions designed to resist proteolytic degradation, allow acylation to further enhance stability, and…”
Luo, Y., Jiang, H., Shi, B., Cai, H., Wang, H., Li, S., Qiu, W., Li, Y., Zhou, R., Deng, H., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108150 · Cited by 10
Self-citationClinical obesity in Asian people: bridging the gap between adiposity and disease
Lim, S.-A., Ji, L., Tham, K. W., Misra, A., & Kadowaki, T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01239-8 · Cited by 20
Self-citationOverweight and Obesity — Capturing the Whole Picture
Aroda, V. R., & Perreault, L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505819 · Cited by 7
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2026) · BMJ · doi:10.1136/bmj-2026-372161 · Cited by 20
Self-citationPark, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“…showed a reduction of 3.41 kg after 33 days of treatment [63], survodutide (BI 45690) demonstrated a 13.8 % reduction in body weight over 16 weeks [64], and phase 3 clinical data for mazdutide (IBI362 / LY3305677) demonstrated a reduction of 14 % bodyweight over 48 weeks of treatment [65].”
InfluentialPatil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
“…Reduces HbA1c and fasting plasma glucose, lowers blood pressure, total cholesterol, LDL and triglycerides [54] ~14% by week 48 [55] Phase 3 trial [55] Subcutaneous,4–6mg,once weekly Dual GLP-1 and GIP receptor agonist [30] Tirzepatide Reduces blood glucose levels [33] Reduces systolic blood…”
Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70263 · Cited by 7
Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026) · Journal of Peptide Science · doi:10.1002/psc.70083 · Cited by 7
“Mazdutide (NCT05607680; GLORY-1) [70] achieved significant weight loss at 32 weeks with a favorable safety profile, and the combination of cagrilintide and semaglutide (CagriSema, NCT05567796; REDEFINE-1) [71] demonstrated superior weight reduction at 68 weeks, high-lighting synergistic effects on…”
Polymeri, A., Feres, M., Giannobile, W. V., & Loos, B. G. (2026) · Journal of Periodontology · doi:10.1002/jper.70092 · Cited by 14
Gao, L., Jiang, H. X., Cai, H., Tian, J., Shi, B., Qiu, W., Huang, C., Han, J., Suhe, Z., Pang, S., et al. (2026) · JAMA · doi:10.1001/jama.2026.8142 · Cited by 10
Self-citationJi, L., Jiang, H., Cheng, Z., Li, X., Pang, S., Zhang, Y., Qiu, W., MA, Q., Liu, Z., Wang, Y., et al. (2026) · Med · doi:10.1016/j.medj.2026.101063 · Cited by 4
Self-citationLempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“These effects are potentially attributable to glucagon-driven hepatic lipid oxidation and purine metabolism [46].”
InfluentialHo, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“Similarly, the GLORY-1 trial investigated the dual GLP-1/glucagon agonist mazdutide in adults with overweight or obesity, demonstrating significant weight loss and metabolic improvements [101].”
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Self-citationPharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026) · Obesity · doi:10.1002/oby.70212 · Cited by 3
Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
“Recent trials, such as those evaluating mazdutide, further indicate the efficacy of these agents in diverse populations, including individuals with obesity and related comorbidities [10].”
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3
Recent progress of remission in type 2 diabetes
Zhao, Z., Yue, H., Zhang, X., Chen, F., Xu, J., & Shao, S. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251408210 · Cited by 4
“112 The increase in bile acid levels in postoperative patients may also play an important role in diabetes remission.”
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Self-citationGLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Evaluation and Management of Obesity in Chronic Kidney Disease
Friedman, A. N. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.07.004 · Cited by 4
Tenecteplase Before Endovascular Thrombectomy (EVT): A Step Forward in Acute Stroke Management
Zubair, M. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07748-4 · Cited by 1
Cheng, W., Chen, Z., Li, P., Zhang, Y., Ma, Y., Liu, P., & Jiang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1654506 · Cited by 1
Self-citationChen, H., Liu, Z., Du, H., Wan, Z., Bai, X., & Mi, J. (2025) · Human Genomics · doi:10.1186/s40246-025-00832-8 · Cited by 1
“Maintaining healthy metabolic status and reversing insulin resistance might be key strategies based on recent clinical trials of SGLT2 inhibitor and glucagon-like peptide-1 and glucagon receptor dual agonist on MASLD treatment [58, 59].”
Self-citationThe dual GLP-1–glucagon agonist pemvidutide in MASH: a phase 2b trial
Tacke, F. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02304-9 · Cited by 3
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
“6 %의 평균 체중 감소를 보였다[ 64 ].”
GLP-1 Is Not Enough: Can Glucagon Fill the Energy Expenditure Gap?
Beji, S., & Caron, A. (2026) · Neuroendocrinology · doi:10.1159/000550812 · Cited by 1
Chan, Z. H., Omar, A. S., Gill, K., Volucke, G., Azhar, M. M., Haleem, S. M., Sia, J. E., Rahman, O. U., Ahmad, M., Shahid, N., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001209 · Cited by 2
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Malik, A., & Malik, R. A. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004250 · Cited by 1
Fasi, M. A. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2645812 · Cited by 1
“Innovent Biologics holds an exclusive license from Eli Lilly and Company to develop and commercialize mazdutide in China [15].”
InfluentialAntza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Recent developments in GPCR signalling in appetite regulation
Brittain, H. R., & Gorvin, C. M. (2026) · Bioscience Reports · doi:10.1042/bsr20250120 · Cited by 1
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
Kamrul-Hasan, A. B. M., Chatterjee, S., Ashraf, H., Nagendra, L., Khalil, I., Hasan, M., Ahsan, A., & Dutta, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71058 · Cited by 1
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Obesity, Visceral Adiposity, and the Future of Hypertension Treatment
Gallagher, B. D. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf175 · Cited by 1
Obesity drugs made in China could power next wave of treatments
Fieldhouse, R. (2025) · Nature · doi:10.1038/d41586-025-01987-z · Cited by 1
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347782
Self-citationFu, W., Zheng, Z., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., & Li, N. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5378169
Glucagon: The Arab Phoenix of the Complex Pathophysiology of Type 2 Diabetes
Prato, S. D., & Bonadonna, R. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf421 · Cited by 1
Collazo–Clavell, M. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2510196
Once-Weekly Mazdutide in Obesity or Overweight
Zhang, Y., Yu, L., & Liu, Z. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2509841
Self-citationEfficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-AnalysisPreprint
Yassin, M. N. A., Sayed, M. S., Saad, O. A., Hussein, Z. A., & Abouelmagd, A. A. (2025) · Research Square · doi:10.21203/rs.3.rs-7884657/v1
Research Progress on Uric Acid and MASLD-Related Liver Fibrosis
苏, 帅. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15103032
van der Giet, M. (2025) · Nephrologie aktuell · doi:10.1055/a-2624-0883
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Novel Therapeutic Strategies for Obesity-Related Glomerulopathy
Liu, Y., Eirin, A., & Lerman, L. O. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01357-0 · Cited by 2
“Anti-obesity medications can be divided into several groups. weight-loss in Chinese adults with overweight or obesity [56].”
Long-term management of body weight and physiological mechanisms of weight regain
Hu, T., & Bao, Y. (2026) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf062 · Cited by 1
“Beyond weight loss, this agent was also shown to reduce liver fat content and improve glycemic control (Zhang et al., 2024 ; Ji et al., 2025 ).”
InfluentialDeng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“The phase 3 GLORY-1 trial was conducted in China and investigated the effects of mazdu-tide 4 mg and 6 mg weekly compared to placebo on weight loss in patients with obesity or overweight based on the Chinese criteria of overweight (BMI 24–27) or obesity ( BMI of ≥ 28 ) [36].”
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
“…GLP-1R 激动 剂不仅具有良好的降糖效果 , 还具备减重 、 心血管保护等 额外获益 [ 11 ] 协同的治疗新基准 [ 12 , 13 ] 。 2025 年 6 月国产全球首个获批 的胰高血糖素受体 GCGR/GLP-1R 双靶减重药物玛仕度 肽上市用于长期肥胖患者的体重控制 [ 14 ] 。 在此基础上 , GLP-1R/GIPR/GCGR 三重激动剂 ( 如瑞 他鲁肽 ) 的研发进一步推动了疗效边界。胰高血糖素受体 ( Glucagon Receptor , GCGR ) 激动具备促进肝脏消耗 、 提高 基础代谢率的能力 , 促进糖异生的风险又可以被 GLP-1R…”
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
“In addition, a recent investigation by Ji et al. (2025) indicated that mazdutide effectively reduces hepatic fat content, demonstrating therapeutic potential comparable to other incretin-based therapies [117].”
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Fu, W., Xu, X., Li, X., Guo, Q., Liu, P., Chen, L., Cheng, W., Zhang, Z., Chen, Z., & Liu, C. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1749194
“Current therapies for HUA and gout primarily focus on restoring UA homeostasis, regulating lipid metabolism, and modulating the gut microbiota; however, knowledge of the intracellular molecular events driving disease progression remains limited (Cheng et al., 2025; Ji et al., 2025; Li et al., 2025).”
Self-citationSimental‐Mendía, L. E., Simental-Mendía, M. A., Aguillón-Marín, P., & Sánchez‐García, A. (2026) · Journal of Investigative Medicine · doi:10.1177/10815589261460894
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
Self-citationPatil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“%) occurred in 73.9% and 82.0% of participants receiving 4.5 and 6 mg, respectively, accompanied by improvements in cardiometabolic parameters and a tolerability profile dominated by limited clinical severity GI adverse events [147].”
InfluentialEkinci, E. I., Maldonado, S. G., Unseld, A., Arrubla, J., Hennige, A. M., & Schoelch, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70861
“Mazdutide (IBI362/LY3305677) has shown greater improvements in FPG, HOMA-IR, and HOMA-β versus placebo in people with type 2 diabetes [58], with similar metabolic benefits reported in people living with overweight or obesity [59].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Alam, A., & Salman, M. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_31_26
Bilal, A. R., Sajid, M., Arfin, S. M. W., Bilal, A. R., Gaba, H., Qureshi, S., Farooq, M. Z., Inam, M. H., Aminpoor, H., & Waqas, S. A. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02000-8 · Cited by 1
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
“Once-weekly subcutaneous injection of mazdutide in clinical trials showed efficacy in treating diabetes and in reducing body weight [49,50].”
Ouyang, Y., Zhong, W., Chen, L., Tang, W., Cao, X., Chu, X., Zhu, D., & Feng, W. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08838-4
“More potent incretin-based agents, including dual and multi-receptor agonists, are now available and have demonstrated greater weight-loss efficacy in other settings [ 35, 36].”
Self-citationClinical Application and Research Progress of Novel Anti-Obesity Medications
商, 博. (2026) · Pharmacy Information · doi:10.12677/pi.2026.154043
Li, Y., Ye, D., Fu, C., Huang, X., Ma, Q., Zhang, F., Chen, G., Song, P., Kong, C., Wu, J., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2687937
“14,15 Therefore, we explored the possibility of AKK components in the modulation of both GLP-1 and GIP.”
Tong, L. H., Leung, K.-K., & Hung, C.-T. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.467288
Kushner, P. R., & Michos, E. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049727 · Cited by 2
Mazdutide and the metabolic treatment revolution
Li, X., Shao, B., Ruan, M., & Yang, S. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.003
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
Bai, X., Zhang, T., Zhang, C., & Li, M. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00076.2026
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
Ji, L., Chen, L., Cheng, Z., Lu, Y., Yang, Y., Fu, F., Zhu, Y., Jin, L., & Kloer, I. M. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01908-x
“However, the T2DM subpopulation had a higher proportion of participants with complications, especially dyslipidemia, hypertension, MASLD, and CVD. Owing to the different inclusion criteria described above, the baseline data exhibited some differences from the SURMOUNT-CN and GLORY-1 trials [32, 33].”
InfluentialSelf-citationFor Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“…(fasted) [244] ~10–65 pM (post-meal) [244] ↑ Blood glucose (glycogenolysis/gluconeogenesis) ↑ Lipolysis [244] Standalone: Approvedfor -1:Phase 2/3[35,247] Amylin Pancreatic β -cells [248] ~2–10 pM (fasted) [249] ~3–11 pM (post-meal) [249] ↑ Satiety ↓ Gastric emptying ↓ Postprandial glucagon [46]…”
InfluentialSelf-citationHe, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Glucagon-like peptide-1 regulates lipid metabolism through actions in the gut and liver
Lewis, G. F., Feng, J. N., & Jin, T. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100023
Hsia, S. H., Bays, H. E., Billings, L. K., Weideman, A. M., Mather, K. J., Coşkun, T., Haupt, A., Thomas, M. K., Tham, L. S., Calderón, B., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00160-9 · Cited by 1
The glucagon renaissance in obesity therapeutics
Muskiet, M. H. A., Bottini, B., Kooijman, S., & Rensen, P. C. N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00187-7
Metadata
- Authors
- Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., Zhong, S., Han, J., Zhang, Y., Lian, Q., Yang, P., Lv, L., Gu, J., Liu, Z., Deng, H., Wang, Y., Li, L., Pei, L., & Qian, L.
- Affiliations
- Peking University People's Hospital (CN)
- Henan University of Science and Technology (CN)
- Nanjing Drum Tower Hospital (CN)
- Central Hospital of Zibo (CN)
- Department of Endocrinology, Luoyang Third People’s Hospital, Luoyang, China
- Nanyang Medical College (CN)
- Shenyang Fifth People Hospital (CN)
- Huzhou Central Hospital (CN)
- Department of Endocrinology, People’s Hospital of Xuancheng, Xuancheng, China
- Suzhou Municipal Hospital (CN)
- First People's Hospital of Kunshan (CN)
- China National Petroleum Corporation (China) (CN)
- Jiangxi Pingxiang People's Hospital (CN)
- Yan'an University (CN)
- Jilin University (CN)
- Lishui Central Hospital (CN)
- Innovent Biologics (China) (CN)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-12
- Volume
- 392
- Issue
- 22
- Pages
- 2215-2225
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410717436
- Cited by
- 125
- References
- 32
- Citations by year
- 2026: 86 · 2025: 39
- FWCI
- 70.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Innovent Biologics
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, overweight, weight loss, GLP-1 receptor agonists, glucagon receptor agonist, weekly dosing, body mass index, weight-related comorbidities, treatment policy estimand, Chinese adults, dose comparison, early discontinuation
- MeSH terms
- East Asian People, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Obesity, Peptides, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.